Aficamten: A New Cardiac Myosin Inhibitor for Hypertrophic Obstructive Cardiomyopathy

Compared to mavacamten, aficamten has lesser potential for drug-drug interactions. Half-life of aficamten in blood is lower so that dose titration is possible within shorter periods than mavacamten, to individualize the dose schedule. The suppressive effect of aficamten on the pumping action of the heart is lower by design so that there is less chance of development of heart failure due to reduced pump function while increasing the dose. In the recent study report there was no loss of benefit in those who were on another group of medications for hypertrophic cardiomyopathy known as beta blockers. It was there in studies on mavacamten earlier.